Gosset Alectos Therapeutics General Information
Alectos Therapeutics is advancing novel small-molecule therapeutics for neurological diseases. Its lead GBA2 inhibitor program (AL01811) is partnered with Biogen for Parkinson's and other lysosomal storage disorders. The OGA inhibitor program, previously partnered with Merck, has returned to Alectos for further development as a potential treatment for Alzheimer's, frontotemporal dementia, ischemic stroke, and TBI. Most programs are preclinical or at the IND application stage; one OGA inhibitor reached Phase 1 clinical trials under Merck partnership. No published clinical efficacy results yet.
Contact Information
Drug Pipeline
Key Partnerships
Biogen – partnership on GBA2 program/AL01811 for neurodegenerative diseases including Parkinson's and lysosomal storage disorders., Merck – previous partnership on first-in-class OGA inhibitors; rights have reverted to Alectos.
Alectos Therapeutics Funding
No funding data available